2020/11/12 11:19:53
In 2020, the U.S. government signed a US $354 million contract with phlow Corporation, a start-up pharmaceutical company, to produce generic drugs and bulk drugs in short supply, while establishing the first strategic reserve of key pharmaceutical ingredients (API) in the United States to reduce dependence on overseas supply (mainly China and India). The start-up will produce API (including precursors) mainly through continuous production.
The four-year contract, signed with the biomedical advanced research and Development Authority (BARDA), can be extended to $812 million in 10 years, one of the largest contracts in BARDA's history. Under the terms of the agreement, phlow will lead a team of private sector entities, including API and intermediate system manufacturers, AMPAC fine chemicals, Civica RX and the medicines for all institute.Phlow indicated that they have started to produce chemical precursors, APIs and final formulations for more than a dozen drugs to treat hospitalized patients with covid-19-related diseases. They also delivered more than 1.6 million doses of five generic drugs for the treatment of covid-19, including tranquilizers, analgesics and antibiotics for patients requiring ventilator support.
